» Articles » PMID: 38473332

The Disproportionate Rise in Pancreatic Cancer in Younger Women Is Due to a Rise in Adenocarcinoma and Not Neuroendocrine Tumors: A Nationwide Time-Trend Analysis Using 2001-2018 United States Cancer Statistics Databases

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2024 Mar 13
PMID 38473332
Authors
Affiliations
Soon will be listed here.
Abstract

In previous studies, a significant increase in the incidence of pancreatic cancer among younger women compared to men in the United States was noted. However, the specific histopathologic characteristics were not delineated. This population-based study aimed to assess whether this disproportionate rise in pancreatic cancer in younger women was contributed by pancreatic ductal adenocarcinoma (PDAC) or pancreatic neuroendocrine tumors (PanNET). The United States Cancer Statistics (USCS) database was used to identify patients with pancreatic cancer between 2001 and 2018. The results showed that, in younger adults, the incidence of PDAC has increased in women [average annual percentage change (AAPC) = 0.62%], while it has remained stable in men (AAPC = -0.09%). The PDAC incidence rate among women increased at a greater rate compared to men with a statistically significant difference in AAPC ( < 0.001), with neither identical nor parallel trends. In contrast, cases of PanNET did not demonstrate a statistically significant sex-specific AAPC difference. In conclusion, this study demonstrated that the dramatic increase in the incidence rate of PDAC explains the disproportionate rise in pancreatic cancer incidence in younger women. This prompts further prospective studies to investigate the underlying reasons for these sex-specific disparities in PDAC.

Citing Articles

Surgical Outcomes in Stage IV Pancreatic Cancer with Liver Metastasis Current Evidence and Future Directions: A Systematic Review and Meta-Analysis of Surgical Resection.

Clements N, Gaskins J, Martin 2nd R Cancers (Basel). 2025; 17(4).

PMID: 40002281 PMC: 11853271. DOI: 10.3390/cancers17040688.


Predictive role of the prognostic nutritional index for long-term prognosis among patients undergoing pancreatoduodenectomy: a meta-analysis.

Liu Y, Li K BMC Surg. 2025; 25(1):51.

PMID: 39881321 PMC: 11776240. DOI: 10.1186/s12893-024-02757-w.


A Population-Based Analysis of the Cancer Incidence in Individuals under 50 in a Northern Italian Province: Focusing on Regional Disparities and Public Health Implications.

Mangone L, Marinelli F, Bisceglia I, Roncaglia F, Morabito F, Testa C Int J Environ Res Public Health. 2024; 21(10).

PMID: 39457306 PMC: 11508065. DOI: 10.3390/ijerph21101333.


Personalized Medicine in Pancreatic Cancer: The Promise of Biomarkers and Molecular Targeting with Dr. Michael J. Pishvaian.

Cortiana V, Abbas R, Chorya H, Gambill J, Mahendru D, Park C Cancers (Basel). 2024; 16(13).

PMID: 39001391 PMC: 11240738. DOI: 10.3390/cancers16132329.

References
1.
Park W, Chawla A, OReilly E . Pancreatic Cancer: A Review. JAMA. 2021; 326(9):851-862. PMC: 9363152. DOI: 10.1001/jama.2021.13027. View

2.
Chen Q, Yuan H, Shi G, Wu Y, Liu D, Lin Y . Association between NR5A2 and the risk of pancreatic cancer, especially among Caucasians: a meta-analysis of case-control studies. Onco Targets Ther. 2018; 11:2709-2723. PMC: 5953269. DOI: 10.2147/OTT.S157759. View

3.
Slade T, Chapman C, Swift W, Keyes K, Tonks Z, Teesson M . Birth cohort trends in the global epidemiology of alcohol use and alcohol-related harms in men and women: systematic review and metaregression. BMJ Open. 2016; 6(10):e011827. PMC: 5093369. DOI: 10.1136/bmjopen-2016-011827. View

4.
Ben Q, Zhong J, Fei J, Chen H, Yv L, Tan J . Risk Factors for Sporadic Pancreatic Neuroendocrine Tumors: A Case-Control Study. Sci Rep. 2016; 6:36073. PMC: 5080551. DOI: 10.1038/srep36073. View

5.
Gaddam S, Abboud Y, Oh J, Samaan J, Nissen N, Lu S . Incidence of Pancreatic Cancer by Age and Sex in the US, 2000-2018. JAMA. 2021; 326(20):2075-2077. PMC: 8543346. DOI: 10.1001/jama.2021.18859. View